Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside.

McDermott SP, Eppert K, Notta F, Isaac M, Datti A, Al-Awar R, Wrana J, Minden MD, Dick JE.

Blood. 2012 Feb 2;119(5):1200-7. doi: 10.1182/blood-2011-01-330019. Epub 2011 Dec 9.

2.

Epigenomics of leukemia: from mechanisms to therapeutic applications.

Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M.

Epigenomics. 2011 Oct;3(5):581-609. doi: 10.2217/epi.11.73. Review.

3.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

4.

Acute myeloid leukaemia in the elderly: a review.

Pollyea DA, Kohrt HE, Medeiros BC.

Br J Haematol. 2011 Mar;152(5):524-42. doi: 10.1111/j.1365-2141.2010.08470.x. Review.

PMID:
21314823
5.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators.

Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3.

PMID:
21131036
6.

(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.

Sharma SK, Wu Y, Steinbergs N, Crowley ML, Hanson AS, Casero RA, Woster PM.

J Med Chem. 2010 Jul 22;53(14):5197-212. doi: 10.1021/jm100217a.

7.

Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development.

Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE.

Nat Immunol. 2010 Jul;11(7):585-93. doi: 10.1038/ni.1889. Epub 2010 Jun 13.

PMID:
20543838
8.

Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.

Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, Edmondson DE, Minucci S, Mattevi A, Mai A.

J Am Chem Soc. 2010 May 19;132(19):6827-33. doi: 10.1021/ja101557k.

PMID:
20415477
9.

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.

Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R.

Int J Cancer. 2011 Feb 1;128(3):574-86. doi: 10.1002/ijc.25349.

10.

Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.

Culhane JC, Wang D, Yen PM, Cole PA.

J Am Chem Soc. 2010 Mar 10;132(9):3164-76. doi: 10.1021/ja909996p.

11.

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.

Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J.

Carcinogenesis. 2010 Mar;31(3):512-20. doi: 10.1093/carcin/bgp324. Epub 2009 Dec 30.

12.

Identification of cell-active lysine specific demethylase 1-selective inhibitors.

Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N.

J Am Chem Soc. 2009 Dec 9;131(48):17536-7. doi: 10.1021/ja907055q.

PMID:
19950987
13.

Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.

Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, Jones RJ, Woster PM, Casero RA Jr.

Clin Cancer Res. 2009 Dec 1;15(23):7217-28. doi: 10.1158/1078-0432.CCR-09-1293. Epub 2009 Nov 24.

14.

Differentiation therapy of acute myeloid leukemia: past, present and future.

Petrie K, Zelent A, Waxman S.

Curr Opin Hematol. 2009 Mar;16(2):84-91. doi: 10.1097/MOH.0b013e3283257aee. Review.

PMID:
19468269
15.

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation.

Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E, Chen T.

Nat Genet. 2009 Jan;41(1):125-9. doi: 10.1038/ng.268. Epub 2008 Dec 21.

PMID:
19098913
16.

A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.

Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA.

Blood. 2009 Jan 29;113(5):1075-85. doi: 10.1182/blood-2008-03-144436. Epub 2008 Oct 23.

17.

A genecentric Human Protein Atlas for expression profiles based on antibodies.

Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ottosson J, Wernérus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Pontén F, Uhlén M.

Mol Cell Proteomics. 2008 Oct;7(10):2019-27. doi: 10.1074/mcp.R800013-MCP200. Review.

18.

DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia.

Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S, Enver T, Hildebrandt G, Zelent A.

Blood. 2008 Feb 15;111(4):2374-7. Epub 2007 Nov 9.

19.

Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells.

McKenzie JL, Gan OI, Doedens M, Dick JE.

Exp Hematol. 2007 Sep;35(9):1429-36. Epub 2007 Jul 25.

PMID:
17656009
20.

Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes.

Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8023-8. Epub 2007 Apr 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk